Skip to content

Tipranavir study halted in treatment-naive

Cost of ARVs makes up less than one third of treatment cost in South African study

Risky sexual behaviour remains low after two years of ART in Uganda

High discordance rates among Ugandan ART clients require new prevention approaches

Fees for HIV treatment increase risk of death in developing countries

Study concludes that interleukin-2 has no benefit before HIV treatment interruptions, but increases side-effects

Liver damage linked to ddI exposure in small series of Spanish patients

Genetic testing can predict who is at risk of abacavir hypersensitivity

Patients taking three-drug NRTI therapy should switch, even if they have durable virological suppression